Immobilized Biotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human NRG1 Beta 1, Fc Tag (Cat. No. NR1-H5268) with a linear range of 0.2-3 ng/mL (QC tested).
The purity of Biotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) is more than 90% and the molecular weight of this protein is around 78-106 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Pharmaceutical Co Ltd | 泰瑞沙, Tagrisso | Mainland China | Carcinoma, Non-Small-Cell Lung | Astrazeneca Ab | 2015-11-13 | Solid tumours; Carcinoma, Bronchogenic; Carcinoma; Thoracic Neoplasms; Bronchial Neoplasms; Lung Diseases; Respiratory Tract Neoplasms; Neoplasms, Nerve Tissue; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
GSK-2849330 | GSK-2849330 | Phase 1 Clinical | Glaxosmithkline Plc | Neoplasms | Details |
Lumretuzumab | RG-7116; RO-5479599 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Recombinant Human Neuromodulin 1-Anti-HER3 Antibody Fusion Protein(Salubris) | SAL-007 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Heart Failure | Details |
Zenocutuzumab | MCLA-128 | Phase 2 Clinical | Merus | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Phase 1 Clinical | Molecular Partners Ag | Neoplasms | Details |
Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis | Details |
Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
Tesevatinib | KD-019; KD-020; XL-647; EXEL-7647 | Phase 3 Clinical | Exelixis Inc | Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Carcinoma, Non-Small-Cell Lung; Polycystic Kidney, Autosomal Recessive; Neoplasm Metastasis | Details |
Recombinant human ErbB3 fragment vaccine (Zensun) | rhErbB3-f | Phase 1 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Neoplasms | Details |
AV-203 | AV-203; CAN-017 | Phase 1 Clinical | Aveo | Solid tumours; Neoplasms | Details |
Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Barecetamab | ISU-104 | Phase 1 Clinical | Isu Abxis | Solid tumours | Details |
KTN-3379 | CDX-3379; KTN-3379 | Phase 2 Clinical | Medimmune | Squamous Cell Carcinoma of Head and Neck; Breast Neoplasms; Thyroid Neoplasms | Details |
Seribantumab | MM-121; SAR-256212; 1N3L70MDFX (UNII code) | Phase 2 Clinical | Merrimack | Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Fallopian Tube Neoplasms; Lung Neoplasms; Uterine Neoplasms; Gallbladder Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Cholangiocarcinoma; Solid tumours; Prostatic Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Kidney Neoplasms | Details |
SI-B001 | SI-B001 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
Patritumab Deruxtecan | U3-1402 | Phase 2 Clinical | Daiichi Sankyo Co Ltd | Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
HMBD-001 | HMBD-001 | Phase 2 Clinical | Hummingbird Bioscience | Solid tumours; Neoplasms | Details |
BL-B01D1 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Neoplasms, Fibroepithelial; Solid tumours; Digestive System Neoplasms; Urologic Neoplasms | Details | |
SIBP-03 | SIBP-03 | Phase 1 Clinical | Shanghai Institute Of Biological Products Co Ltd | Neoplasms | Details |
Recombinat humanized HER3-targeting antibody | Phase 1 Clinical | Shanghai Institute Of Biological Products Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.